See also this year's filing and all EDGAR filings for this company.
PDF Report 0001114220_2017_Keryx_Biopharmaceuticals_INC.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| warning | Similarly named company. Duplicate? | None | {'details': [{'other_company': 'Provectus Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}, {'other_company': 'Regenerx Biopharmaceuticals INC', 'shared_tokens': {'biopharmaceuticals'}}]} |
| warning | Missing logo | subcommand.report | {} |
Graph
Absolute values for 0001114220, Keryx Biopharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 132,897,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 3,208,000 |
| 2 | PropertyPlantAndEquipmentNet | 4,211,000 |
| 3 | remainder_Assets | 1,111,000 |
| 4 | LiabilitiesCurrent | 21,551,000 |
| 5 | LiabilitiesNoncurrent | 1,040,000 |
| 6 | remainder_Liabilities | 127,132,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 86,895,204 |
| 9 | ResearchAndDevelopmentExpense | 29,572,150 |
| 10 | remainder_Expenses | 210,944,000 |
| 11 | remainder_Revenues | 51,787,800 |
| 12 | remainder_NetIncome | -67,483,954 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 141,427,000 |
| 1 | Liabilities | 149,723,000 |
| 2 | Expenses | 327,411,354 |
| 3 | Revenues | 51,787,800 |
| 4 | StockholdersEquity | -8,296,000 |
| 5 | NetIncome | -343,107,508 |
| 6 | ComprehensiveNetIncome | -343,107,508 |
| 7 | BaseVar | 368,916,554 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -2.48 |
| 9 | EconomicCapitalRatio | 0.862 |
Edgar->Model Mapping
Feature Distribution
Change over Time
